Sanofi Launches Care Path Educator Role for tzield in Los Angeles, Aiming to Support Newly Approved Type 1 Diabetes Treatment
LOS ANGELES – Sanofi has established a new Care Path Educator position based in Los Angeles to support the rollout of Tzield (teplizumab-mzwv), the first disease-modifying treatment for delaying the onset of stage 3 type 1 diabetes. The role will focus on educating healthcare professionals and patients about Tzield and navigating the care pathway.
Sanofi is offering a thorough rewards package, health and wellbeing benefits-including at least 14 weeks’ gender-neutral parental leave-and a company car through its FLEET programme to the triumphant candidate.All applicants must complete fleet safety training and maintain an acceptable driving record.
Tzield received FDA approval in November 2022 and is indicated to delay the onset of stage 3 type 1 diabetes in at-risk individuals aged 8 years and older whose stage 2 type 1 diabetes has been confirmed by a positive test for islet autoantibodies.
Sanofi emphasizes its commitment to diversity and inclusion, stating it is an Equal opportunity and Affirmative Action employer. Further benefits facts is available at https://benefits.sanofiusallwell.com/fleet/public/index/ba511bf8-5c32-4828-9861-ab985fffab90/?cid=sanofi. Those needing assistance with the online application process can find resources at https://jobs.sanofi.com/en/request-for-reasonable-accommodation.
